Vaginal cuff brachytherapy (VBT) is a critical part of a radiation oncologist's practice and is routinely offered both at academic sites and within the community. However, in the modern era, many are stretched increasingly thin and have fewer resources to work with.
There have been many advancements in terms of treatment and imaging modalities for patients with oligometastatic prostate cancer. Failure to understand these advancements in treatment options leads to lower quality of care delivered by clinicians treating prostate cancer patients.
Radiation and immunotherapies are commonly utilized sequentially or concurrently for the treatment of cancer patients, yet we are still developing our understanding of the optimal approaches for safely and effectively integrating these treatments.
MRI-guided Radiation Therapy (MRgRT), FLASH proton therapy, concurrent immunotherapy, and radiation therapy and SBRT for oligometastatic disease, are emerging technologies and approaches to optimize cancer care.
Patients with Stage IV Lung cancer vary in their response to the numerous systemic therapies and are living longer. The role of aggressive local therapy or metastatic directed therapy (MDT) is critical for radiation oncologists and surgeons.
Given the rate of scientific advances over the past 20 years, it is difficult for practicing radiation oncologists to stay abreast of the latest drugs, their targets and mechanisms of action.
The use of SABR is well established in many cancers, however, its application within kidney cancer is relatively new. This is largely due to the historical notion that renal cell carcinoma (RCC) is highly radioresistant.
SBRT for oligometastatic disease of mixed histologies has been shown to improve progression-free and even overall survival. A large cooperative group study recently demonstrated that there was no overall survival advantage seen when constrained to breast cancer alone.